{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:34:56Z","timestamp":1791340496906,"version":"4.3.1"},"reference-count":48,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies of mature T lymphocytes with 5-year overall survival rates of only \u223c 35%. Improvement in outcomes has been stymied by poor understanding of the genetics and molecular pathogenesis of PTCL, with a resulting paucity of molecular targets for therapy. We developed bioinformatic tools to identify chromosomal rearrangements using genome-wide, next-generation sequencing analysis of mate-pair DNA libraries and applied these tools to 16 PTCL patient tissue samples and 6 PTCL cell lines. Thirteen recurrent abnormalities were identified, of which 5 involved p53-related genes (TP53, TP63, CDKN2A, WWOX, and ANKRD11). Among these abnormalities were novel TP63 rearrangements encoding fusion proteins homologous to \u0394Np63, a dominant-negative p63 isoform that inhibits the p53 pathway. TP63 rearrangements were seen in 11 (5.8%) of 190 PTCLs and were associated with inferior overall survival; they also were detected in 2 (1.2%) of 164 diffuse large B-cell lymphomas. As TP53 mutations are rare in PTCL compared with other malignancies, our findings suggest that a constellation of alternate genetic abnormalities may contribute to disruption of p53-associated tumor suppressor function in PTCL.<\/jats:p>","DOI":"10.1182\/blood-2012-03-419937","type":"journal-article","created":{"date-parts":[[2012,8,2]],"date-time":"2012-08-02T01:32:22Z","timestamp":1343871142000},"page":"2280-2289","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":218,"title":["Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas"],"prefix":"10.1182","volume":"120","author":[{"given":"George","family":"Vasmatzis","sequence":"first","affiliation":[{"name":"Center for Individualized Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Center for Individualized Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"Knudson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Viswanatha","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Sertac","family":"Kip","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazan","family":"\u00d6zsan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ege University, Izmir, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan K.","family":"Grebe","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori A.","family":"Frederick","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce W.","family":"Eckloff","sequence":"additional","affiliation":[{"name":"Advanced Genomics Technology Center, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Aubrey","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall E.","family":"Kadin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Roger Williams Medical Center, Providence, RI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragana","family":"Milosevic","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie C.","family":"Porcher","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan W.","family":"Asmann","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David I.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina V.","family":"Kovtun","sequence":"additional","affiliation":[{"name":"Center for Individualized Medicine, Mayo Clinic, Rochester, MN;"},{"name":"Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"10","key":"2019111810104600000_B1","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"12","key":"2019111810104600000_B2","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"2019111810104600000_B3","article-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","volume-title":"World Health Organization Classification of Tumours","author":"Swerdlow","year":"2008","edition":"4 Ed"},{"issue":"25","key":"2019111810104600000_B4","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma.","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111810104600000_B5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccr.2010.11.033","article-title":"ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.","volume":"18","author":"Gerber","year":"2010","journal-title":"Cancer Cell"},{"issue":"3","key":"2019111810104600000_B6","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/leu.2008.320","article-title":"Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.","volume":"23","author":"Feldman","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"2019111810104600000_B7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2010-08-303305","article-title":"Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively-parallel genomic sequencing.","volume":"117","author":"Feldman","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111810104600000_B8","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/modpathol.2010.225","article-title":"Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.","volume":"24","author":"Wada","year":"2011","journal-title":"Mod Pathol"},{"issue":"1","key":"2019111810104600000_B9","first-page":"57","article-title":"Role of p63 in cancer development.","volume":"1816","author":"Graziano","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"2019111810104600000_B10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1309\/PNXUKA1CFJMVGCN1","article-title":"Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization.","volume":"130","author":"Feldman","year":"2008","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"2019111810104600000_B11","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2008.77","article-title":"Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"2019111810104600000_B12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2141.2008.07207.x","article-title":"Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation.","volume":"142","author":"Costa","year":"2008","journal-title":"Br J Haematol"},{"issue":"7-8","key":"2019111810104600000_B13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.clinbiochem.2010.01.016","article-title":"Development and validation of a comprehensive mutation and deletion detection assay for SDHB, SDHC, and SDHD.","volume":"43","author":"Milosevic","year":"2010","journal-title":"Clin Biochem"},{"issue":"1-2","key":"2019111810104600000_B14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mrfmmm.2004.08.021","article-title":"INK4a\/ARF: a multifunctional tumor suppressor locus.","volume":"576","author":"Sharpless","year":"2005","journal-title":"Mutat Res"},{"issue":"52","key":"2019111810104600000_B15","doi-asserted-by":"crossref","first-page":"43100","DOI":"10.1074\/jbc.M505590200","article-title":"WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53.","volume":"280","author":"Chang","year":"2005","journal-title":"J Biol Chem"},{"issue":"Pt 21","key":"2019111810104600000_B16","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1242\/jcs.026351","article-title":"Identification of ANKRD11 as a p53 coactivator.","volume":"121","author":"Neilsen","year":"2008","journal-title":"J Cell Sci"},{"issue":"3","key":"2019111810104600000_B17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/01.pai.0000142160.52670.ce","article-title":"Expression of p63 in diffuse large B-cell lymphoma.","volume":"13","author":"Hedvat","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"18","key":"2019111810104600000_B18","first-page":"4855","article-title":"Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.","volume":"54","author":"Greenblatt","year":"1994","journal-title":"Cancer Res"},{"issue":"2","key":"2019111810104600000_B19","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/hupa.2001.21569","article-title":"Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations.","volume":"32","author":"Petit","year":"2001","journal-title":"Hum Pathol"},{"issue":"9","key":"2019111810104600000_B20","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.leu.2403840","article-title":"p53 gene mutations are uncommon but p53 is commonly expressed in anaplastic large-cell lymphoma.","volume":"19","author":"Rassidakis","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"2019111810104600000_B21","first-page":"573","article-title":"Post-thymic T cell lymphomas frequently overexpress p53 protein but infrequently exhibit p53 gene mutations.","volume":"144","author":"Matsushima","year":"1994","journal-title":"Am J Pathol"},{"issue":"7","key":"2019111810104600000_B22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm0798-839","article-title":"Cloning and functional analysis of human p51, which structurally and functionally resembles p53.","volume":"4","author":"Osada","year":"1998","journal-title":"Nat Med"},{"issue":"5","key":"2019111810104600000_B23","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1172\/JCI30866","article-title":"The p63\/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers.","volume":"117","author":"Leong","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111810104600000_B24","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2005.12.013","article-title":"p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis.","volume":"9","author":"Rocco","year":"2006","journal-title":"Cancer Cell"},{"issue":"21","key":"2019111810104600000_B25","first-page":"7113","article-title":"Significance of p63 amplification and overexpression in lung cancer development and prognosis.","volume":"63","author":"Massion","year":"2003","journal-title":"Cancer Res"},{"issue":"19","key":"2019111810104600000_B26","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.1158\/0008-5472.CAN-06-1619","article-title":"Tumor-specific p73 up-regulation mediates p63 dependence in squamous cell carcinoma.","volume":"66","author":"DeYoung","year":"2006","journal-title":"Cancer Res"},{"issue":"4-5","key":"2019111810104600000_B27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.drup.2008.08.001","article-title":"Therapeutic prospects for p73 and p63: rising from the shadow of p53.","volume":"11","author":"Vilgelm","year":"2008","journal-title":"Drug Resist Updat"},{"issue":"7318","key":"2019111810104600000_B28","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nature09459","article-title":"TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs.","volume":"467","author":"Su","year":"2010","journal-title":"Nature"},{"issue":"12","key":"2019111810104600000_B29","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/ncb1988","article-title":"TAp63 induces senescence and suppresses tumorigenesis in vivo.","volume":"11","author":"Guo","year":"2009","journal-title":"Nat Cell Biol"},{"issue":"3","key":"2019111810104600000_B30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1097-2765(00)80275-0","article-title":"p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.","volume":"2","author":"Yang","year":"1998","journal-title":"Mol Cell"},{"issue":"1","key":"2019111810104600000_B31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/jcp.21656","article-title":"Overexpression of delta Np63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation.","volume":"219","author":"Chiang","year":"2009","journal-title":"J Cell Physiol"},{"issue":"3","key":"2019111810104600000_B32","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/35043127","article-title":"P63 and P73: P53 mimics, menaces and more.","volume":"1","author":"Yang","year":"2000","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"30","key":"2019111810104600000_B33","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1038\/sj.onc.1203656","article-title":"High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?","volume":"19","author":"Crook","year":"2000","journal-title":"Oncogene"},{"issue":"2","key":"2019111810104600000_B34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbrc.2010.04.093","article-title":"Dominant negative (DeltaN) p63alpha induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways.","volume":"396","author":"Mundt","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2019111810104600000_B35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.4161\/cc.6.3.3803","article-title":"p63 transcriptional regulation of epithelial integrity and cancer.","volume":"6","author":"Trink","year":"2007","journal-title":"Cell Cycle"},{"issue":"26","key":"2019111810104600000_B36","doi-asserted-by":"crossref","first-page":"23906","DOI":"10.1074\/jbc.M300746200","article-title":"P63 alpha mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome.","volume":"278","author":"Fomenkov","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"2019111810104600000_B37","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1021\/pr9011156","article-title":"Identification of DeltaNp63alpha protein interactions by mass spectrometry.","volume":"9","author":"Amoresano","year":"2010","journal-title":"J Proteome Res"},{"issue":"24","key":"2019111810104600000_B38","doi-asserted-by":"crossref","first-page":"8748","DOI":"10.1523\/JNEUROSCI.0681-11.2011","article-title":"DeltaNp63 regulates stem cell dynamics in the mammalian olfactory epithelium.","volume":"31","author":"Packard","year":"2011","journal-title":"J Neurosci"},{"issue":"2","key":"2019111810104600000_B39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.2478\/s11658-011-0009-9","article-title":"The role of p63 in cancer, stem cells and cancer stem cells.","volume":"16","author":"Nekulova","year":"2011","journal-title":"Cell Mol Biol Lett"},{"issue":"3","key":"2019111810104600000_B40","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2141.2009.07739.x","article-title":"The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target.","volume":"146","author":"Cheung","year":"2009","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111810104600000_B41","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/blood-2012-02-414441","article-title":"TBL1XR1\/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.","volume":"119","author":"Scott","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2019111810104600000_B42","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V91.8.2977.2977_2977_2984","article-title":"p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.","volume":"91","author":"Pinyol","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2019111810104600000_B43","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/modpathol.2009.196","article-title":"CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma.","volume":"23","author":"Laharanne","year":"2010","journal-title":"Mod Pathol"},{"issue":"3","key":"2019111810104600000_B44","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1006\/geno.2002.6828","article-title":"Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes.","volume":"80","author":"Powell","year":"2002","journal-title":"Genomics"},{"issue":"23","key":"2019111810104600000_B45","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/onc.2011.456","article-title":"Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11.","volume":"31","author":"Noll","year":"2012","journal-title":"Oncogene"},{"issue":"9","key":"2019111810104600000_B46","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood-2007-02-075069","article-title":"Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.","volume":"110","author":"Jenner","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111810104600000_B47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/jid.2010.271","article-title":"Primary cutaneous CD30+ anaplastic large-cell lymphomas show a heterogeneous genomic profile: an oligonucleotide arrayCGH approach.","volume":"131","author":"Sanchez-Schmidt","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"20","key":"2019111810104600000_B48","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1158\/0008-5472.CAN-09-4521","article-title":"Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.","volume":"70","author":"Hastak","year":"2010","journal-title":"Cancer Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/11\/2280\/1358310\/zh803712002280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/11\/2280\/1358310\/zh803712002280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T10:53:05Z","timestamp":1574074385000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/11\/2280\/30221\/Genomewide-analysis-reveals-recurrent-structural"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,13]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,9,13]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-419937","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,13]]}}}